Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON41971
NL-OMON41971
Completed
Phase 3

Prospective multicenter clinical trial with the PRECIZION Presbyopic multifocal intraocular lens - PRECIZION Presbyopic clinical trial

OPHTEC BV0 sites10 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCataractPresbyopia10047518

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Cataract
Sponsor
OPHTEC BV
Enrollment
10
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

Trial is onging in other countries

Registry
who.int
Start Date
TBD
End Date
November 7, 2016
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
OPHTEC BV

Eligibility Criteria

Inclusion Criteria

  • •\* Patient must be 45 years of age or older
  • •\* Presbyopic
  • •\* Cataract patient or Clear Lens Extraction (CLE) candidate
  • •\* Patient wishes to be spectacle independent for near and far vision
  • •\* Patient lifestyle and outlook fit with multifocal IOL implantation
  • •\* Qualifies for bilateral implantation
  • •\* Patients must have a calculated IOL power within the available diopter range
  • •\* Expected best corrected visual acuity of 0\.5 or better after IOL implantation
  • •\* No secondary surgical procedure planned during the course of the study
  • •\* Availability, willingness and sufficient cognitive awareness and physical ability to comply with examination procedures throughout the entire duration of the study

Exclusion Criteria

  • •\* Ocular disease other than cataract that may predispose for future complications or might confound the outcome of the investigation (e.g anterior segment pathology, glaucoma, corneal dystrophy, ocular inflammation, pseudoexfoliation syndrome, retinal disorders)
  • •\* Acute or chronic disease or illness or use of medication that could confound the outcome of the study or increase the risk to the subject
  • •\* Endothelial cell count \<1500 cells/mm2
  • •\* Amblyopia
  • •\* Congenital eye abnormalities
  • •\* Previous ocular surgery that might confound the outcome of the investigation or increase risk to patient.
  • •\* Concurrent participation or participation during the last 30 days in any other clinical trial
  • •\* Patient must not be pregnant or has another condition with associated fluctuation of hormones that could lead to refractive changes

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
A prospective randomised controlled multicentre trial comparing half-dose photodynamic therapy (PDT) with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (CSC).Chronic central serous chorioretinopathy10047060
NL-OMON39842niversitair Medisch Centrum119
Completed
N/A
A multicentre Prospective study in pAtients undergoing ventral herNia repair by open approach with intrA-peritoneal positioning using parietex* Composite vEntral pAtch.hernia / abdominal wall defect10041297
NL-OMON40149Covidien8
Completed
N/A
Multicenter randomized clinical trial in Patients with Juvenile Idiopathic Arthritis and Methotrexate related side effects: Psychological Behavioural therapy versus switch to MTX parenteral versus standard of care
NL-OMON38373niversitair Medisch Centrum Utrecht450
Completed
N/A
A prospective, multi-centre study investigating the incidence and prognosis of relapses, pseudo-relapses and other causes of (sub)acute neurological symptoms in patients with relapsing-remitting multiple sclerosis.
NL-OMON55562Sint Elisabeth Ziekenhuis125
Completed
Phase 4
A Prospective, Randomized, Multi-center Study to Assess the SaFety of the Orsiro Mission Stent compared to the ResoLute Onyx Stent in Subjects at High Risk for Bleeding in combination With 1-month Dual Antiplatelet Therapy (DAPT).
NL-OMON52323BIOTRONIK AG1